Trials / Completed
CompletedNCT01849107
Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Small bowel irradiation results in epithelial cell loss and consequently impairs function and metabolism. A metabolic end product of small bowel enterocytes is plasma citrulline. The investigators evaluate the correlation between plasma citrulline level, dose-volume histogram of small bowel, and small bowel toxicity grade by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE ver.4.0) to investigate whether citrulline can be used as a biomarker for quantifying radiation-induced epithelial cell loss.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Plasma citrulline |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2013-12-01
- Completion
- 2014-12-01
- First posted
- 2013-05-08
- Last updated
- 2020-01-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01849107. Inclusion in this directory is not an endorsement.